Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer.

[1]  J. Mu,et al.  Retracted: Long Non‐coding RNA Linc‐ITGB1 Knockdown Inhibits Cell Migration and Invasion in GBC‐SD/M and GBC‐SD Gallbladder Cancer Cell Lines , 2015, Chemical biology & drug design.

[2]  P. Hu,et al.  MiR-183 Regulates ITGB1P Expression and Promotes Invasion of Endometrial Stromal Cells , 2015, BioMed research international.

[3]  Heping Cheng,et al.  STIM1- and Orai1-mediated Ca2+ oscillation orchestrates invadopodium formation and melanoma invasion , 2014, The Journal of cell biology.

[4]  M. Hou,et al.  STIM1 Overexpression Promotes Colorectal Cancer Progression, Cell Motility and COX-2 Expression , 2014, Oncogene.

[5]  D. Ma,et al.  Activation of integrin β1 mediates the increased malignant potential of ovarian cancer cells exerted by inflammatory cytokines. , 2014, Anti-cancer agents in medicinal chemistry.

[6]  M. Hou,et al.  Computational Analysis of mRNA Expression Profiles Identifies the ITG Family and PIK3R3 as Crucial Genes for Regulating Triple Negative Breast Cancer Cell Migration , 2014, BioMed research international.

[7]  Qian Ning,et al.  Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. , 2014, Molecular and clinical oncology.

[8]  J. Parker,et al.  MicroRNA 9-3p Targets β1 Integrin To Sensitize Claudin-Low Breast Cancer Cells to MEK Inhibition , 2013, Molecular and Cellular Biology.

[9]  King-Jen Chang,et al.  Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas , 2012, PloS one.

[10]  J. Zanetti,et al.  Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study , 2012, Diagnostic Pathology.

[11]  Adam V Jones,et al.  MicroRNA‐124 suppresses oral squamous cell carcinoma motility by targeting ITGB1 , 2011, FEBS letters.

[12]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Fan Zhang,et al.  Expression profiling of integrins in lung cancer cells. , 2009, Pathology, research and practice.

[14]  L. Carey,et al.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. , 2009, Clinical breast cancer.

[15]  Xin-Yun Huang,et al.  Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. , 2009, Cancer cell.

[16]  N. Lin,et al.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.

[17]  Daniel Birnbaum,et al.  How basal are triple‐negative breast cancers? , 2008, International journal of cancer.

[18]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[20]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[21]  Dan H. Moore,et al.  Increased β1 Integrin Is Associated with Decreased Survival in Invasive Breast Cancer , 2007 .

[22]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[24]  Jeffrey Wyckoff,et al.  Cell migration in tumors. , 2005, Current opinion in cell biology.

[25]  J. Putney,et al.  Store-operated calcium channels. , 2005, Physiological reviews.

[26]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[27]  B. Davidson,et al.  αV- and β1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients , 2003 .

[28]  G. Davis,et al.  α4β1 Integrin Activation of L-Type Calcium Channels in Vascular Smooth Muscle Causes Arteriole Vasoconstriction , 2002 .

[29]  S. Ethier,et al.  Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. , 2001, Cancer research.

[30]  S. Eom,et al.  Calreticulin couples calcium release and calcium influx in integrin-mediated calcium signaling. , 2000, Molecular biology of the cell.

[31]  O. Cussenot,et al.  Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. , 1997, European journal of cancer.

[32]  A. Jara-Lazaro,et al.  Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer , 2010, Modern Pathology.

[33]  W. Dong,et al.  Expression of putative stem cell genes Musashi-1 and β1-integrin in human colorectal adenomas and adenocarcinomas , 2009, International Journal of Colorectal Disease.

[34]  Lodewyk F. A. Wessels,et al.  Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response , 2009, Breast Cancer Research and Treatment.

[35]  Hui Zhang,et al.  Increased beta1 integrin is associated with decreased survival in invasive breast cancer. , 2007, Cancer research.

[36]  B. Davidson,et al.  AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. , 2003, Gynecologic Oncology.